Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

@article{Ravandi2009SuperiorOW,
  title={Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities},
  author={Farhad Ravandi and Jean-Pierre Issa and Guillermo Garcia-Manero and Susan M O'Brien and Sherry A. Pierce and Jianqin Shan and Gautam Borthakur and Srdan Verstovsek and Stefan H Faderl and Jorge E. Cortes and Hagop M Kantarjian},
  journal={Cancer},
  year={2009},
  volume={115 24},
  pages={
          5746-51
        }
}
BACKGROUND Outcome of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with chromosome 5 and 7 abnormalities (excluding del 5[q]) has been poor, with <10% of patients alive at 2 years. METHODS The authors investigated whether treatment with hypomethylating agents (5-azacytidine/decitabine) leads to an improved outcome. Between January 2004 and December 2007, 81 patients (37 [46%] with AML [>or=20% blasts]; 44 [54%] with high-risk MDS) with chromosome 5… CONTINUE READING
Highly Cited
This paper has 75 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

75 Citations

01020'11'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 75 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007
View 1 Excerpt

Phase I study of suberoylanilide hydroxamic acid ( SAHA ) and decitabine in patients with relapsed , refractory or poor prognosis leuke

R Ravandi, S Faderl, D Thomas
Blood • 2007

Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis

R Ravandi, S Faderl, D Thomas
leuke- mia. Blood • 2007
View 1 Excerpt